Nilofer Azad
SKCCC Johns Hopkins Medical Institution · Sidney Kimmel Comprehensive Cancer Center at the Johns Hopkins Medical Institution · SKCCC at the Johns Hopkins Medical Institution
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Registry trials as an overall official
20
all conditions, ClinicalTrials.gov
NIH grants tied to them
5
1 more share only the name and are not shown
Trial papers
68
PubMed author-name match
Trials
Studies that name Nilofer Azad as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 16:53 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT06411691 · KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal CancerSidney Kimmel Comprehensive Cancer Center at Johns Hopkins · recruiting · Colorectal Cancer, Pancreatic Cancer · principal investigator
- Ph1NCT05013216 · Mutant KRAS -Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic CancerSidney Kimmel Comprehensive Cancer Center at Johns Hopkins · active not recruiting · High Risk Cancer, Pancreatic Cancer · principal investigator
- Ph1NCT04799431 · Neoantigen-Targeted Vaccine Combined With Anti-PD-1 Antibody for Patients With Stage IV MMR-p Colon and Pancreatic Ductal CancerSidney Kimmel Comprehensive Cancer Center at Johns Hopkins · withdrawn · Pancreatic Cancer Metastatic, Colorectal Cancer Metastatic · principal investigator
- Ph1NCT04117087 · Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected Mismatch Repair Protein (MMR-p) Colorectal and Pancreatic CancerSidney Kimmel Comprehensive Cancer Center at Johns Hopkins · active not recruiting · Colorectal Cancer, Pancreatic Cancer · principal investigator
- Ph2NCT04116073 · INCMGA00012 in Patients With Previously Treated Unresectable or Metastatic Adenosquamous Pancreatic or Ampullary CancerSidney Kimmel Comprehensive Cancer Center at Johns Hopkins · completed · Pancreatic Cancer Non-resectable, Pancreatic Cancer Metastatic · principal investigator
- Ph1NCT03875287 · Dose-Escalation Study of E7727, an Oral Cytidine Deaminase Inhibitor With Oral Decitabine in Subjects With Solid TumorsSidney Kimmel Comprehensive Cancer Center at Johns Hopkins · active not recruiting · Solid Tumor · principal investigator
- Ph1/Ph2NCT03711058 · Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal CancerSidney Kimmel Comprehensive Cancer Center at Johns Hopkins · completed · Unresectable or Metastatic Microsatellite Stable (MSS) Solid Tumor, Microsatellite Stable (MSS) Colon Cancer · principal investigator
- Ph1NCT03471286 · A Window of Opportunity Study to Investigate Mechanisms of Actions of Novel Therapeutic Agents in Patients With Resectable Solid Tumor MalignanciesSidney Kimmel Comprehensive Cancer Center at Johns Hopkins · terminated · Solid Tumor · principal investigator
- Ph2NCT03250273 · A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic AdenocarcinomaSidney Kimmel Comprehensive Cancer Center at Johns Hopkins · completed · Metastatic Cholangiocarcinoma, Cholangiocarcinoma, Pancreatic Cancer · principal investigator
- Ph1/Ph2NCT03058289 · A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6Intensity Therapeutics, Inc. · completed · Breast Cancer, Head and Neck Cancer, Squamous Cell Carcinoma · principal investigator
- Ph2NCT02981524 · Study of GVAX (With CY) and Pembrolizumab in MMR-p Advanced Colorectal CancerSidney Kimmel Comprehensive Cancer Center at Johns Hopkins · completed · Metastatic Colorectal Cancer · principal investigator
- Ph1NCT02512172 · A Study of Enhancing Response to MK-3475 in Advanced Colorectal CancerSidney Kimmel Comprehensive Cancer Center at Johns Hopkins · completed · Colorectal Cancer · principal investigator
- Ph1NCT01966289 · SGI-110 in Combination With an Allogeneic Colon Cancer Cell Vaccine (GVAX) and Cyclophosphamide (CY) in Metastatic Colorectal Cancer (mCRC)Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · completed · Metastatic Colorectal Cancer · principal investigator
- Ph2NCT01845805 · Trial to Improve Outcomes in Patients With Resected Pancreatic Cancer (Azacitidine)Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · completed · Pancreatic Cancer · principal investigator
- Ph1NCT01783171 · Dinaciclib and Akt Inhibitor MK2206 in Treating Patients With Pancreatic Cancer That Cannot Be Removed by SurgeryNational Cancer Institute (NCI) · completed · Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma, Stage III Pancreatic Cancer AJCC v6 and v7 · principal investigator
- Ph2NCT01639131 · Gemcitabine and Docetaxel in Patients With Relapsed or Refractory Metastatic Colorectal AdenocarcinomaSidney Kimmel Comprehensive Cancer Center at Johns Hopkins · terminated · Metastatic Colorectal Adenocarcinoma · principal investigator
- Ph1NCT01537744 · A Trial of Oral 5-azacitidine in Combination With Romidepsin in Advanced Solid Tumors, With an Expansion Cohort in Virally Mediated Cancers and LiposarcomaSidney Kimmel Comprehensive Cancer Center at Johns Hopkins · completed · Solid Tumors, Virally Mediated Cancers and Liposarcoma · principal investigator
- Ph1NCT01264432 · Veliparib and Radiation Therapy in Treating Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis, Epithelial Ovarian, Fallopian, or Primary Peritoneal CancerNational Cancer Institute (NCI) · completed · Adult Solid Neoplasm, Peritoneal Carcinomatosis, Recurrent Fallopian Tube Carcinoma · principal investigator
- Ph2NCT01105377 · Azacitidine and Entinostat in Treating Patients With Metastatic Colorectal CancerNational Cancer Institute (NCI) · completed · Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IV Colon Cancer · principal investigator
- Ph1NCT01061749 · Selumetinib and Cixutumumab in Treating Patients With Advanced Solid MalignanciesNational Cancer Institute (NCI) · completed · Adult Solid Neoplasm · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 16:53 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Cancer Genetics and EpigeneticsP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · fiscal years 2022 to 2026 · $302,314 awarded in 2026Grant number is on one of their registry trials
- Molecular Targets for Cancer Detection and TreatmentT32CA009071 · NCI · JOHNS HOPKINS UNIVERSITY · fiscal years 2020 to 2026 · $517,188 awarded in 2026Same name and institution; not confirmed by an ID
- Optimization of an active mutant KRAS peptide vaccine in colorectal cancerR01CA296410 · NCI · JOHNS HOPKINS UNIVERSITY · fiscal years 2025 to 2026 · $590,629 awarded in 2026Grant number is on one of their registry trials
- Mechanisms of immunomodulation with epigenetic therapyP01CA247886 · NCI · JOHNS HOPKINS UNIVERSITY · fiscal years 2021 to 2025 · $313,219 awarded in 2025Grant number is on one of their registry trials
- Targeting RAS signaling with CDK and AKT inhibition in pancreatic cancerR21CA172997 · NCI · JOHNS HOPKINS UNIVERSITY · fiscal years 2013 to 2014 · $170,891 awarded in 2014Grant number is on one of their registry trials
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Administrative CoreP50CA062924 · NCI · JOHNS HOPKINS UNIVERSITY · PI Alison P Klein · fiscal years 2016 to 2022Named on NCT04799431, NCT04116073
- Neoantigen-Targeted Vaccines in Combination with Immune Checkpoint Inhibitors for Pancreatic CancerK08CA248624 · NCI · JOHNS HOPKINS UNIVERSITY · PI Neeha Zaidi · fiscal years 2021 to 2025Named on NCT04117087
- U01CA132123RePORTER returned no project for this number; it is shown as the registry gives it.Named on NCT01783171, NCT01264432
- U01CA070095RePORTER returned no project for this number; it is shown as the registry gives it.
- North American Star ConsortiumUM1CA186644 · NCI · UNIVERSITY HEALTH NETWORK · PI Philippe Bedard, Kevin D Courtney, Steven Grant, Salma Jabbour, Jeffrey Lancet, Devalingam Mahalingam, Lillian L Siu, JONATHAN C TRENT · fiscal years 2016 to 2026Named on NCT01783171, NCT01264432
- Texas EXperimental Cancer Therapeutics Network - TEX CTNUM1CA186688 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI FUNDA MERIC-BERNSTAM, John Sarantopoulos, James C Yao · fiscal years 2016 to 2026Named on NCT01783171
- The Johns Hopkins Translational Science Team and Consortium for ETCTN StudiesUM1CA186691 · NCI · JOHNS HOPKINS UNIVERSITY · PI Jan Hendrik Beumer, Michael A Carducci, Ryan Gentzler, GLENN LIU, Wells A. Messersmith, Jimmy Ruiz · fiscal years 2016 to 2026
- Wisconsin and New Jersey Alliance in Precision Experimental TherapeuticsUM1CA186716 · NCI · RBHS -CANCER INSTITUTE OF NEW JERSEY · PI Salma Jabbour, GLENN LIU · fiscal years 2016 to 2019Named on NCT01783171
- Pathology Research Shared ResourceP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI THOMAS J FLOTTE · fiscal years 2016 to 2026Named on NCT01105377
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 16:53 UTC. The ranking covers the 200 most relevant of 68 PubMed records, and a shared surname and initials can bring in a namesake. All 68 on PubMed
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.N Engl J Med · 20157,784 citationsRCR 243.1
- 5,520 citationsRCR 184.9
- Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers.Oncotarget · 2014357 citationsRCR 8.9
- Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study.Lancet Oncol · 2021353 citationsRCR 19.3
- Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity.J Clin Oncol · 2008266 citationsRCR 5.9
- Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study.Lancet Gastroenterol Hepatol · 2019171 citationsRCR 6.0
- Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors.Cancer Chemother Pharmacol · 2014163 citationsRCR 3.9
- Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses.J Natl Cancer Inst · 2014149 citationsRCR 3.8
- 127 citationsRCR 4.5
- Nivolumab Is Effective in Mismatch Repair-Deficient Noncolorectal Cancers: Results From Arm Z1D-A Subprotocol of the NCI-MATCH (EAY131) Study.J Clin Oncol · 2020115 citationsRCR 4.1